白血球分離術市場 - 全球產業規模、佔有率、趨勢、機會及預測（按類型、應用、最終用戶、地區和競爭格局分類，2021-2031年）

全球白血球分離術市場預計將從 2025 年的 8,349 萬美元成長到 2031 年的 1.1427 億美元，複合年成長率為 5.37%。

白血球分離術是一種特殊的醫療程序，透過該程序將白血球從血液樣本中分離出來，並將剩餘成分輸回患者的循環系統。市場成長的主要促進因素是：由於血液系統骨髓惡性腫瘤分離術的需求不斷增加，以控制白血球計數升高；此外，細胞免疫療法研究的擴展也需要高品質的白血球包用於先進的治療藥物生產。近期統計數據凸顯了這種臨床緊迫性：根據美國癌症協會預測，2024年美國預計將新增約62,770例白血病病例，這凸顯了高效細胞分離技術對於支持持續治療和監測通訊協定的重要性。

儘管成長要素強勁，但由於血液分離設備和手術成本高昂，市場仍面臨許多障礙。自動化設備所需的高額資本投入，加上一次性試劑盒的持續成本，限制了小規模醫療機構的普及，也阻礙了成本敏感型發展中地區的推廣應用。這些經濟限制有效地限制了這些關鍵技術的廣泛應用，並阻礙了小規模醫療機構購置服務患者群體所需的必要基礎設施。

市場促進因素

CAR-T細胞療法的快速商業化已成為全球白血球分離術市場的主要催化劑，顯著提高了自體T細胞採集的分離系統使用率。隨著監管機構將這些治療方法的核准擴大到更早的治療方案，生產網路面臨著快速擴大規模以應對更大患者數量的壓力，這就需要建立更密集的、具備分離術能力的採集中心基礎設施。這種商業性動能也體現在依賴這些流程的關鍵市場產品的財務成功上。根據強生公司2024年10月發布的2024年第三季財報，其用於治療多發性骨髓瘤的CAR-T療法Carvykti的全球營業銷售額達到2.86億美元，年增87.6%。如此快速的收入成長表明患者可及性不斷提高，並且與生產這些個人化療法所需的採集流程數量增加直接相關，從而推動了市場擴張。

同時，免疫腫瘤學和細胞療法臨床試驗的激增顯著提高了對臨床治療和用於製程開發的研究級白血球包裝的需求。研發人員依賴可靠的高品質細胞材料供應，以檢驗生產流程並對新候選藥物進行安全性測試，從而確保血球分離術提供者的持續收入來源。根據美國基因與細胞治療學會於2024年4月發布的《2024年第一季基因、細胞和RNA療法趨勢報告》，全球在開發平臺基因、細胞和RNA治療方法已擴展至4021種，涵蓋從臨床前到註冊前的各個階段。這項大規模的研究工作得到了聯邦政府的大力支持，包括美國國家癌症研究所2024會計年度72.2億美元的營運預算，這些資金有助於穩定供應鏈，並確保臨床和實驗室環境中對白血球分離技術的穩定需求。

市場挑戰

白血球分離設備和營運成本帶來的沉重經濟負擔是市場擴張的主要障礙。自動化血球分離設備需要高額的資本投入，因此只有資金雄厚的大型醫療中心和核心實驗室才能負擔得起。這項經濟門檻使得小規模的醫療機構和社區診所，尤其是在對成本高度敏感的發展中地區，難以獲得這項關鍵技術，從而限制了設備的安裝數量和可服務的患者數量。

除了初始設備購置成本外，市場還面臨來自一次性試劑盒和維護成本持續上漲的壓力。這些營運費用直接影響手術的成本效益和血液製品的最終價格。近期產業數據也印證了這個成本上漲趨勢。根據美國血液和生物治療促進協會 (AABB) 發布的《2025 年全國血液採集和利用調查報告》，醫院購買單採血小板的平均價格較上一報告週期上漲了 65 美元/單位。單採血小板成分成本的上漲給醫療機構帶來了沉重的經濟負擔，最終迫使他們限制治療量，並阻礙了依賴白血球分離術的治療方法的廣泛應用。

市場趨勢

攜帶式和移動式白血球分離設備的興起，透過分散獲取關鍵細胞材料的途徑，從根本上改變了市場格局。自主型行動採血中心的引進，克服了過去阻礙偏遠和醫療資源匱乏地區捐血者參與的後勤障礙。這種轉變使得在社區內直接收集高品質的白血球分離包成為可能，減輕了患者前往固定中心的負擔。近期旨在擴大細胞治療供應鏈地理覆蓋範圍的基礎建設，正是此一趨勢的體現。根據BioBridge Global在2025年5月發布的新聞稿，該公司宣布運作首個移動式白血球分離中心，該中心旨在為超過63,000平方英里的區域提供醫療服務，顯著擴大免疫細胞採集的覆蓋範圍。

同時，封閉式自動化處理平台的引進正在影響市場，這要求上游工程必須與無菌生產流程相容。隨著細胞療法開發商從手動開放式實驗室操作轉向全自動生態系統，對能夠與下游生物反應器無縫整合以最大限度降低污染風險和人事費用的白血球分離產品的需求日益成長。這種向自動化的轉變確保了細胞材料在整個靜脈到靜脈流程的活性和一致性。近期的行業合作已證實了此類整合系統的有效性。Terumo Corporation血液與細胞技術公司和芝加哥大學於2025年11月宣布，研究人員使用Quantum Flex平台在10天內成功將1000萬個外周血單核細胞（PBMC）擴增至90億個，證明了有效整合採集和處理技術所能實現的擴充性。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球白血球分離術市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依類型（白血球去除設備、血球分離設備、白血球去除柱、細胞分離器、白血球去除過濾器、白血球去除耗材）
  • 依用途（研究用途、治療用途）
  • 按最終用戶分類（血液成分供應商和血液中心、學術研究機構、製藥和生物技術公司、醫院、輸血中心）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章 北美白血球分離術市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲白血球分離術市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區白血球分離術市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲白血球分離術市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章 南美白血球分離術市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球白血球分離術市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Asahi Kasei Medical Co. Ltd
• Haemonetics Corporation
• TERUMO BCT INC.
• STEMCELL Technologies Canada Inc.
• Fresenius SE & Co. KGaA
• B. Braun SE
• Caltag Medsystems Limited
• Precision Medicine Group, LLC
• LMB Technologie GmbH
• Grifols, SA
• Kaneka Pharma Europe NV

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Leukapheresis Market is projected to expand from USD 83.49 Million in 2025 to USD 114.27 Million by 2031, registering a CAGR of 5.37%. Leukapheresis is a specialized medical procedure wherein white blood cells are separated from drawn blood, while the remaining components are returned to the patient's circulation. Market growth is primarily driven by the increasing prevalence of hematological malignancies, which fuels the demand for therapeutic apheresis to manage elevated white blood cell counts, and the expansion of cell-based immunotherapy research necessitating high-quality leukopaks for the manufacturing of Advanced Therapy Medicinal Products. This clinical urgency is highlighted by recent statistics; according to the American Cancer Society, approximately 62,770 new cases of leukemia were projected to be diagnosed in the United States in 2024, underscoring the critical need for efficient cellular separation technologies to support ongoing treatment and research protocols.

Despite these robust growth drivers, the market faces a significant hurdle due to the substantial costs associated with apheresis equipment and procedures. The high capital expenditure required for automated devices, combined with the recurring expenses for disposable kits, limits accessibility for smaller healthcare facilities and creates barriers to adoption in cost-sensitive developing regions. These financial constraints effectively restrict the widespread implementation of these essential technologies, preventing smaller institutions from acquiring the necessary infrastructure to serve their patient populations.

Market Driver

The rapid commercialization of CAR-T cell therapies acts as a primary catalyst for the global leukapheresis market, significantly increasing the utilization of apheresis systems for harvesting autologous T-cells. As regulatory bodies extend approvals for these treatments to earlier lines of therapy, manufacturing networks are compelled to scale rapidly to handle larger patient volumes, necessitating a denser infrastructure of collection centers capable of performing apheresis. This commercial momentum is reflected in the financial success of key market products dependent on these procedures; according to Johnson & Johnson's 'Q3 2024 Earnings Report' from October 2024, worldwide operational sales for Carvykti, a CAR-T therapy for multiple myeloma, rose by 87.6% year-over-year to $286 million. Such swift revenue growth indicates broadened patient access and directly correlates with a higher number of collection procedures needed to produce these personalized treatments, thereby fueling market expansion.

Concurrently, a surge in immuno-oncology and cell therapy clinical trials is substantially boosting the demand for both clinical procedures and research-grade leukopaks used in process development. Developers depend on consistent access to high-quality cellular starting materials to validate manufacturing processes and conduct safety studies for new candidates, ensuring a continuous revenue stream for apheresis providers. According to the American Society of Gene + Cell Therapy's 'Gene, Cell, + RNA Therapy Landscape Q1 2024 Quarterly Report' released in April 2024, the global pipeline has grown to include 4,021 gene, cell, and RNA therapies in development, spanning from preclinical to pre-registration stages. This extensive research activity is supported by significant federal investment, such as the National Cancer Institute's 2024 operating budget of $7.22 billion, which helps stabilize the supply chain and ensures a steady requirement for leukapheresis technologies in both clinical and laboratory settings.

Market Challenge

The significant financial burden associated with leukapheresis equipment and operational expenses serves as a major obstacle to broader market growth. Automated apheresis devices require a high capital expenditure, effectively limiting their acquisition to large, well-funded medical centers and reference laboratories. This financial threshold prevents smaller healthcare facilities and community clinics, particularly in cost-sensitive developing regions, from adopting these essential technologies, thereby restricting the overall installed base and limiting the volume of patients who can access these services.

In addition to the initial asset purchase, the market faces sustained pressure from rising recurring costs related to disposable kits and maintenance. These operational expenses directly impact the affordability of procedures and the final cost of blood products. This upward cost trajectory is confirmed by recent industry data; according to the Association for the Advancement of Blood & Biotherapies (AABB) in 2025, findings from the National Blood Collection and Utilization Survey indicated that the median price hospitals paid for apheresis-derived platelets increased by $65 per unit compared to the previous reporting cycle. Such escalating costs for apheresis-derived components place an economic strain on healthcare providers, ultimately forcing them to limit procedure volumes and hindering the widespread scalability of leukapheresis-dependent therapies.

Market Trends

The rise of portable and mobile leukapheresis units is fundamentally reshaping the market by decentralizing access to essential cellular starting materials. By deploying self-contained, mobile collection centers, providers can circumvent logistical barriers that historically restricted donor participation in remote or underserved areas. This shift enables the collection of high-quality leukopaks directly within communities, reducing the burden on patients who previously had to travel to fixed-site reference centers. This trend is illustrated by recent infrastructure developments aimed at extending the geographic reach of cell therapy supply chains; according to BioBridge Global's May 2025 press release regarding the launch of their first mobile leukapheresis center, the new unit is designed to support healthcare services across a region exceeding 63,000 square miles, significantly expanding the catchment area for immune cell collection.

Simultaneously, the adoption of closed-system automated processing platforms is influencing the market by necessitating upstream compatibility with sterile manufacturing workflows. As cell therapy developers transition from manual, open-lab procedures to fully automated ecosystems, there is a heightened requirement for leukapheresis products that integrate seamlessly with downstream bioreactors to minimize contamination risks and labor costs. This move towards automation ensures that the cellular starting material retains viability and consistency throughout the vein-to-vein process. The efficacy of such integrated systems is demonstrated by recent industry collaborations; according to a November 2025 announcement by Terumo Blood and Cell Technologies and the University of Chicago, researchers successfully expanded 10 million PBMCs to 9 billion cells in 10 days using the Quantum Flex platform, proving the scalability achievable when collection and processing technologies are effectively aligned.

Key Market Players

• Asahi Kasei Medical Co. Ltd
• Haemonetics Corporation
• TERUMO BCT INC.
• STEMCELL Technologies Canada Inc.
• Fresenius SE & Co. KGaA
• B. Braun SE
• Caltag Medsystems Limited
• Precision Medicine Group, LLC
• LMB Technologie GmbH
• Grifols, S.A.
• Kaneka Pharma Europe NV

Report Scope

In this report, the Global Leukapheresis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Leukapheresis Market, By Type

• Leukapheresis Devices
• Apheresis Devices
• Leukapheresis Columns
• Cell Separators
• Leukoreduction Filters
• Leukapheresis Disposables

Leukapheresis Market, By Application

• Research Applications
• Therapeutic Applications

Leukapheresis Market, By End User

• Blood Component Providers and Blood Centers
• Academic and Research Institutes
• Pharmaceutical and Biotechnology Companies
• Hospitals
• Transfusion Centers

Leukapheresis Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Leukapheresis Market.

Available Customizations:

Global Leukapheresis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Leukapheresis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Leukapheresis Devices, Apheresis Devices, Leukapheresis Columns, Cell Separators, Leukoreduction Filters, Leukapheresis Disposables)
  • 5.2.2. By Application (Research Applications, Therapeutic Applications)
  • 5.2.3. By End User (Blood Component Providers and Blood Centers, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Hospitals, Transfusion Centers)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Leukapheresis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Leukapheresis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Leukapheresis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Leukapheresis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Leukapheresis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Leukapheresis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Leukapheresis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Leukapheresis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Leukapheresis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Leukapheresis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Leukapheresis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Leukapheresis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Leukapheresis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Leukapheresis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Leukapheresis Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Leukapheresis Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Leukapheresis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Leukapheresis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Leukapheresis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Leukapheresis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Leukapheresis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Leukapheresis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Leukapheresis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Leukapheresis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Leukapheresis Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Asahi Kasei Medical Co. Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Haemonetics Corporation
• 15.3. TERUMO BCT INC.
• 15.4. STEMCELL Technologies Canada Inc.
• 15.5. Fresenius SE & Co. KGaA
• 15.6. B. Braun SE
• 15.7. Caltag Medsystems Limited
• 15.8. Precision Medicine Group, LLC
• 15.9. LMB Technologie GmbH
• 15.10. Grifols, S.A.
• 15.11. Kaneka Pharma Europe NV

16. Strategic Recommendations

17. About Us & Disclaimer